First New HIV Vaccine Efficacy Study in Seven Years Has Begun

South Africa Hosts Historic NIH-Supported Clinical Trial
National Institutes of Health, November 27, 2016

Read online at:
https://www.niaid.nih.gov/news-events/first-new-hiv-vaccine-efficacy-study-seven-
years-has-begun
pic-001

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus. HVTN 702 aims to enroll 5,400 men and women, making it the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people become infected with HIV every day.

(Visited 19 times, 1 visits today)
This entry was posted in Essential Medicines, General, HIV - AIDS - STI. Bookmark the permalink.